Turkish Journal of Medical Sciences最新文献

{"title":"Association between papillary thyroid cancer and <i>XRCC6</i> gene polymorphisms in the Turkish population.","authors":"Egemen Akgün, Fadime Mutlu Içduygu, Demet Şengül, Ebru Alp, Mehmet Alkanat, Ayşegül Çebi, Tuncer Öztürk","doi":"10.55730/1300-0144.5902","DOIUrl":"10.55730/1300-0144.5902","url":null,"abstract":"<p><strong>Background/aim: </strong>To investigate the association between the rs2267437, rs5751129 and rs132770 polymorphisms of the <i>XRCC6</i> gene, which plays a role in repairing DNA double-strand breaks, and the risk of papillary thyroid carcinoma (PTC).</p><p><strong>Materials and methods: </strong>The study included 150 patients who had been diagnosed with PTC and 204 healthy controls. Genotyping of the SNPs was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).</p><p><strong>Results: </strong>In the rs2267437 polymorphism, individuals with the GG genotype had lower risk of PTC than those with the wild-type CC genotype (p = 0.037, 95% CI: 0.19-0.96, OR: 0.67). The combined genotypes CG+GG were related to a reduced risk of PTC compared to the wild-type CC genotype (p = 0.023, 95% CI: 0.40-0.94, OR: 0.61) in the recessive model (GC+GG vs. CC). In addition, a query of the genotype-tissue expression (GTEx) database showed that the rs2267437 polymorphism may alter the expression level of <i>XRCC6</i> in whole blood (p = 0.0009) but not in thyroid tissue. There were no significant associations between the rs5751129 and rs132770 polymorphisms and PTC.</p><p><strong>Conclusion: </strong>This study demonstrated that rs2267437 polymorphism may have a protective effect against PTC in the Turkish population. However, the rs5751129 and rs132770 polymorphisms were not associated with the disease.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 6","pages":"1215-1222"},"PeriodicalIF":1.2,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are there differences in the clinical and laboratory features of patients with seronegative primary Sjögren's syndrome?","authors":"Müçteba Enes Yayla, Rahime Aksoy, Emine Uslu, Zehra Karaman, Recep Yilmaz, Ahmet Ilbay, Nilgün Göveç Giynaş, Abdulbaki Gaydan, Ahmet Usta, Yeter Mahmutoğlu, Aşkın Ateş, Murat Turgay","doi":"10.55730/1300-0144.5873","DOIUrl":"https://doi.org/10.55730/1300-0144.5873","url":null,"abstract":"<p><strong>Background/aim: </strong>The objective of this study was to demonstrate the commonalities and distinctions between patients with seronegative and seropositive primary Sjögren's syndrome (pSS).</p><p><strong>Materials and methods: </strong>The records of 399 patients with pSS seen between January 2010 and June 2023 were retrospectively examined. Patients with negative antiSSA/Ro, antiSSB/La, ANA, and RF antibodies comprised the seronegative group, while patients with at least one positive antibody were included in the seropositive group.</p><p><strong>Results: </strong>The most common clinical features between the groups were arthralgia (81.2%), arthritis (11.5%), hematological involvement (19.8%), and pulmonary involvement (11.8%). In 41 patients (10.3%), no autoantibody positivity was detected. The number of patients with at least one extraarticular involvement was statistically more frequent in the seropositive group (p = 0.011). Dry mouth was found to be more prevalent among seronegative patients (p = 0.003). While hyperimmune gammaglobulinemia exhibited a higher prevalence within the seropositive group (p = 0.004), the occurrence of reduced complement levels was at similar rates in both groups. All deaths were observed exclusively within the seropositive group (17/358, 4.7%). No difference was observed between the two groups concerning mortality (p = 0.237) and malignancies (seropositive group: 9/358, 2.5% vs. seronegative group: 3/41, 7.3%, p = 0.115). There was a statistically significant association between low C4 levels (OR = 2.99 [1.09-8.16], p = 0.045 in model 1, OR = 3.10 [1.14-8.42], p = 0.022 in model 2), and the extraarticular findings.</p><p><strong>Conclusion: </strong>While hematological, renal, pulmonary, and neurological involvements are observed with similar frequency in both seronegative and seropositive pSS patients, the presence of extraarticular manifestations was more common in seropositive patients. Additionally, there was a relationship between extraarticular involvement and low C4 levels.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 5","pages":"956-962"},"PeriodicalIF":1.2,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexisting growing teratoma syndrome and gliomatosis peritonei following ovarian immature teratoma: a case report and literature review.","authors":"Osman Türkmen, Serra Akar Inan, Serap Akbay, Mohammad İbrahim Halilzade, İnci Halilzade, Özlem Moraloğlu Tekin","doi":"10.55730/1300-0144.5899","DOIUrl":"10.55730/1300-0144.5899","url":null,"abstract":"<p><p>Growing teratoma syndrome (GTS) is characterized by a reduction in serum tumor markers despite the growth of a benign mature teratomatous mass following chemotherapy for germ cell tumors. Gliomatosis peritonei (GP) typically accompanies ovarian teratomas, marked by the dissemination of mature glial tissue across the peritoneum. The concurrent presence of GTS and GP after treatment for ovarian immature teratoma (IMT) is notably rare, with approximately 20 reported cases. This case involves a 25-year-old patient who underwent surgical removal of an adnexal mass, which was later diagnosed as stage IIIA grade 3 ovarian IMT with parametrial involvement. Following two cycles of bleomycin, etoposide, and cisplatin chemotherapy, imaging identified new lesions adjacent to the liver and on the pelvic peritoneum. A second fertility-sparing surgery was performed, and paraffin pathology confirmed a mature teratoma within the excised specimen. Additionally, the resected pelvic peritoneum revealed nodules of mature glial tissue consistent with GP. The coexistence of GP with GTS post-IMT surgery presents a diagnostic challenge in distinguishing between malignant and benign components, which is critical to avoid unnecessarily aggressive surgical and chemotherapeutic treatments. Recognizing such cases may enable fertility-sparing surgery for these patients.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 6","pages":"1192-1197"},"PeriodicalIF":1.2,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nationwide study on the prevalence of rheumatoid factor and anticitrullinated peptide positivity and their contribution to rheumatoid arthritis diagnosis.","authors":"Hasan Satiş, Abdulsamet Erden, Emre Bilgin, Gizem Ayan, Berkan Armağan, Duygu Tecer, Alper Sari, Umut Kalyoncu, Murat Çağlayan, Mustafa Mahir Ülgü, Mustafa Okan Ayvali, Naim Ata, Şuayip Birinci","doi":"10.55730/1300-0144.5872","DOIUrl":"https://doi.org/10.55730/1300-0144.5872","url":null,"abstract":"<p><strong>Background/aim: </strong>Rheumatoid factor (RF) and anticitrullinated peptide (anti-CCP) are specific for rheumatoid arthritis (RA) diagnosis. However, they could be positive in other diseases and even in healthy populations. The aim was to investigate the prevalence of positive RF and anti-CCP antibodies in persons admitted to hospital for any reason and on a national scale.</p><p><strong>Materials and methods: </strong>The National Electronic Health Database, which contains the clinical records of over 80 million people, was used to design this multicenter, retrospective cohort study. The subjects included in the study were divided into age groups according to 10-year periods. RA cases were identified using ICD-10 codes that included M05, M06, M08, and their subgroups. RF and anti-CCP positivity were evaluated in terms of their contribution to the risk of being diagnosed with RA, with the change according to age and sex.</p><p><strong>Results: </strong>During the 1.1.2018-31.12.2021 period, 13,918,072 RF tests were performed in 11,849,440 people, whereas 1,183,607 anti-CCP tests were performed in 1,020,967 people. Moreover, 797,089 people had both tests performed at least once. The RF positivity rate in patients who only requested RF tests was 14.72% and it was 35.04% for anti-CCP positivity in those who only requested anti-CCP tests. The rate of concomitant RF and anti-CCP positivity was 22.56%. An RA diagnosis was made in 27.8% of RF-positive people, 39.73% of anti-CCP-positive people, and 56.6% of co-RF and anti-CCP-positive people. RF positivity and concomitant RF and anti-CCP positivity increased with age and were more common in females.</p><p><strong>Conclusion: </strong>RF and anti-CCP positivity may be seen in a healthy population with female predominance. As age increases, the risk of RF positivity rises, but anti-CCP positivity does not change. Concomitant RF and anti-CCP positivity shows the highest risk of RA development with respect to either antibody positivity alone.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 5","pages":"949-955"},"PeriodicalIF":1.2,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the efficacy of transfer energy capacitive and resistive therapy in patients with knee osteoarthritis.","authors":"Özge Tezen, Emine Esra Bilir, Öznur Uzun, Duygu Yaniktaş, Başak Şentürk, Evren Yaşar","doi":"10.55730/1300-0144.5913","DOIUrl":"10.55730/1300-0144.5913","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to compare the therapeutic efficacy of conventional physical therapy (CPT) methods for knee osteoarthritis (OA) and transfer energy capacitive and resistive (TECAR) therapy, a relatively new and increasingly used treatment modality, based on patient clinical outcomes assessments.</p><p><strong>Materials and methods: </strong>Two groups of 54 patients, aged 40 to 75, were randomly assigned. CPT was given to both groups. In addition to CPT, Group 2 underwent TECAR therapy for six sessions, three times a week for two weeks. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) was used to measure the disability and pain levels of each patient before and at the end of treatment and at 1 month and 3 months. Additionally, goniometric measurements of each patient's knee joint range of motion and isometric quadriceps muscle strength were taken.</p><p><strong>Results: </strong>Significant improvements were noted in the VAS, WOMAC, and isometric quadriceps strength ratings in both groups between the pre- and posttreatment follow-ups. However, there was no discernible difference between the groups.</p><p><strong>Conclusion: </strong>For the conservative treatment of OA in the knee, TECAR therapy may be a helpful therapeutic approach.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 6","pages":"1302-1309"},"PeriodicalIF":1.2,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new scoring in differential diagnosis: multisystem inflammatory syndrome or adenovirus infection?","authors":"Mustafa Gençeli, Talha Üstüntaş, Özge Metin Akcan, Sinan Saylik, Fatih Ercan, Sevgi Pekcan, Sipil Gençeli, Sevgi Yaşar Durmuş, Mustafa Argun","doi":"10.55730/1300-0144.5905","DOIUrl":"10.55730/1300-0144.5905","url":null,"abstract":"<p><strong>Background/aim: </strong>Differentiating multisystem inflammatory syndrome in children (MIS-C) from adenovirus infection (AI) can be challenging due to similar clinical and laboratory findings. This study aimed to identify distinguishing characteristics and develop a scoring system to facilitate accurate diagnosis.</p><p><strong>Materials and methods: </strong>A comprehensive review of medical records was undertaken for 108 MIS-C patients and 259 patients with confirmed AI. A comparison of laboratory data and clinical findings was conducted across the patient groups using appropriate statistical tests.</p><p><strong>Results: </strong>The MIS-C patients were significantly older than the AI patients (p < 0.001). Diarrhea, rash, abdominal pain, vomiting, nonexudative conjunctivitis, lymphadenopathy tachycardia, bradycardia, hypotension, hypoxia seizures, agitation, headache, and altered consciousness symptoms were more frequently associated with MIS-C (p < 0.001), while cough and runny nose were significantly more common in AI (p < 0.001). Lymphopenia and thrombocytopenia were more prevalent in the MIS-C patients (p < 0.001). AI and MIS-C were scored by giving one point each to the parameters that created the difference. For AI, being ≤60 months of age, the presence of cough, runny nose and absence of diarrhea, rash, abdominal pain, vomiting, nonexudative conjunctivitis, lymphadenopathy, tachycardia, bradycardia, hypotension, hypoxia seizures, agitation, headache, and altered consciousness, lymphopenia, thrombocytopenia, and C-reactive protein value <124.5 mg/L were determined as each parameter plus one point. A total score above 14 could predict AI with a high degree of accuracy, with sensitivity at around 97.5% and specificity at 92.6%.</p><p><strong>Conclusion: </strong>The proposed inpatient scoring system, when used in conjunction with polymerase chain reaction testing, may improve the early differentiation of AI and MIS-C. This approach could help reduce unnecessary testing and optimize resource allocation. Further research with larger samples should investigate this novel scoring system to establish its reliability and generalizability.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 6","pages":"1237-1243"},"PeriodicalIF":1.2,"publicationDate":"2024-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid and cardiovascular diseases.","authors":"Sinem Başak Tan Öksüz, Mustafa Şahin","doi":"10.55730/1300-0144.5927","DOIUrl":"10.55730/1300-0144.5927","url":null,"abstract":"<p><p>The thyroid gland is one of the major regulator organs of hemostasis in the human body, controlling the functioning of numerous systems. Thyroid hormones exert a modulating effect on the cardiovascular system in particular, ensuring optimal functioning within the normal range. Triiodothyronine (T3), as an active form of thyroid hormone, is mainly responsible for this effect via both genomic and nongenomic mechanisms. It has been reported that overt thyroid disorders are associated with a number of cardiovascular diseases and cardiac mortality. While hyperthyroidism appears to be related to atrial fibrillation and heart failure, the most pronounced cardiovascular complication of hypothyroidism seems to be atherosclerosis. Achieving euthyroidism is of great importance for restoring cardiovascular function. However, depending on the underlying health conditions, this may not be possible for all patients. Furthermore, there has been a growing focus on the role of subclinical thyroid dysfunctions and their impacts on the cardiovascular system in recent years. The pattern of cardiovascular abnormalities in subclinical thyroid disorders appears to parallel that of overt hypothyroidism, suggesting that even mild alterations in thyroid hormone levels may also have effects on the cardiovascular system. The management of subclinical thyroid disease remains controversial. Current evidence suggests that patient age and underlying cardiovascular diseases are major factors in clinical decision-making.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 7","pages":"1420-1427"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"A retrospective study on the clinical and molecular outcomes of calpainopathy in a Turkish patient cohort\": [Turkish Journal of Medical Sciences 54 (1) 2024 86-98].","authors":"İzem Olcay Şahin, Emine Karataş, Mikail Demir, Büşra Tan, Hüseyin Per, Yusuf Özkul, Munis Dündar","doi":"10.55730/1300-0144.5861","DOIUrl":"10.55730/1300-0144.5861","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.55730/1300-0144.5769.].</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 4","pages":"880"},"PeriodicalIF":1.2,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11407355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In silico study of bioactive compounds derived from Indonesian marine invertebrates as a novel antituberculosis agent.","authors":"Ayu Masyita, Eris Septiana, Asep Bayu, Bustanussalam Bustanussalam, Jonathan A Panggabean, Firdayani Firdayani, Tutik Murniasih","doi":"10.55730/1300-0144.5923","DOIUrl":"10.55730/1300-0144.5923","url":null,"abstract":"<p><strong>Background/aim: </strong>Tuberculosis (TB) has become the world's deadliest disease. The lack of an effective therapeutic drug to treat it is one of the obstacle for doctors. Today, multidrug-resistant TB cases are increasing. Investigating these new drug should be given intensive and careful consideration. Marine invertebrates are valuable since they produce a large number of active compounds, and screening of these active compounds is very important.</p><p><strong>Materials and methods: </strong>Anti-TB screening of compounds derived from marine invertebrates was performed via the in silico method. Three-dimensional structures of pantothenate kinase (MtPanK type 1, PDB ID: 4BFT), <i>Mycobacterium tuberculosis</i> InhA (PDB ID: 2X23), protein kinase B (PDB ID: 5U94), and β-ketoacyl acyl carrier protein synthase I (MtKasA, PDB ID: 2WGE) were used as the protein targeted receptors.</p><p><strong>Results: </strong>The molecular docking analysis showed that the potential candidate compounds with the lowest docking score were 19-hydroxypsammaplysin Q, 19-hydroxypsammaplysin S, psammaplysin L, and psammaplysin K dimethoxy acetal. Several compounds, such as molamide C and the manzamine group, are also potential anti-TB compounds.</p><p><strong>Conclusion: </strong>This study showed that psammaplysin groups have potential as anti-TB compounds. Further laboratory experiments should be done to confirm the in silico data.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 6","pages":"1399-1408"},"PeriodicalIF":1.2,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with morbidity of a totally implantable venous access device in patients with breast cancer.","authors":"Burak Ilhan, Berkay Kiliç","doi":"10.55730/1300-0144.5904","DOIUrl":"10.55730/1300-0144.5904","url":null,"abstract":"<p><strong>Background/aim: </strong>To investigate the possible morbidities associated with the implantation of a totally implantable venous access device (TIVAD) in breast cancer (BC) patients.</p><p><strong>Materials and methods: </strong>Clinical data and developed complications in 546 BC patients with TIVAD between 2017 and 2021 were analyzed retrospectively. Among these, 524 (96%) patients who underwent TIVAD implantation via the right subclavian vein (SCV) route were examined separately.</p><p><strong>Results: </strong>The mean patient age was 56.1 ± 11.4 years, and the mean patient body mass index was 25.3 ± 6.5. The incidence of early complications was 2.3% (12 cases), and the late complication incident rate was 2.6% (14 cases). Among these complications, ten (1.9%) catheter-related infections developed more frequently than others. Early complications increased as the number of puncture attempts rose and decreased with ultrasound guidance in the implantation, but no other predictive factors increased. No correlation existed between the patients' age, body mass index, BC side, puncture method, puncture number, surgical approach, radiotherapy, and late complications. There was no evidence that postoperative effects specific to BC surgery, such as increased pain, decreased functional capacity, and lymphedema, were altered with TIVAD implantation. For catheter-related infections only, adjuvant radiotherapy was a risk factor for patients with various comorbidities.</p><p><strong>Conclusion: </strong>This study concludes that the right SCV approach remains a morbidity-safe route for TIVAD implantation in BC patients, as in other malignancies. The study suggests that clinicians can use other implantation routes to avoid catheter-related infection in patients scheduled for neoadjuvant treatment, who also have morbidity, and who are likely to receive postoperative radiotherapy.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"54 6","pages":"1230-1236"},"PeriodicalIF":1.2,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}